In short
A long-acting analog of growth hormone-releasing hormone (GHRH). Small human studies exist; it was never approved. Health Canada names it among unauthorized peptides it has seized.
Also known asoften sold blended with ipamorelin
CategoryGrowth hormone
Canada statusNot authorized in Canada
Human evidence Limited: small or low-quality human studies
Sport (WADA)WADA's Prohibited List bans growth hormone releasing factors and secretagogues (S2) at all times.
Last reviewedNovember 10, 2026
How strong is the human evidence?
- Cell & animal
- Small human studies
- Some randomized trials
- Large randomized trials
What is CJC-1295?
CJC-1295 is a modified GHRH designed to last longer in the blood, so the body releases more growth hormone (GH) and IGF-1 for days.
It is widely sold online, often as a "CJC-1295/ipamorelin" blend.
Is CJC-1295 legal in Canada?
Not authorized. Listed by Health Canada among unauthorized peptides being sold and among seized injectables (April 2026 advisory).
What the research shows
- Teichman et al. (J Clin Endocrinol Metab 2006): two small placebo-controlled trials in healthy adults found dose-dependent rises in GH (2–10-fold for 6+ days) and IGF-1 (1.5–3-fold); no serious adverse reactions were reported over 28–49 days.
What it doesn't show
- Raising GH and IGF-1 on a lab test is not the same as showing benefits like muscle, fat loss, recovery or anti-ageing. We found no such outcome trials.
- No long-term human safety data.
Common questions
Is CJC-1295 legal in Canada?
No. Health Canada lists CJC-1295 among unauthorized peptides it has found and seized.
Is CJC-1295 a steroid?
No. It is a peptide that signals the pituitary to release growth hormone. It is still a drug, and it is banned in sport.
Sources
- Health Canada — Peptides: Overview
- Health Canada advisory RA-81874 (Apr 9, 2026): Think twice before injecting peptides bought online
- Teichman SL et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults. JCEM 2006
- World Anti-Doping Agency — Prohibited List
Related
IpamorelinA growth hormone-releasing peptide described in 1998 as the first selective GH secretagogue. Never approved; Health…Not authorized in Canada
SermorelinA shortened form of natural GHRH, reviewed in 1999 for use in children with growth hormone deficiency. We found no…Not authorized in Canada
TesamorelinA GHRH analog studied and approved for excess abdominal fat in people with HIV-associated lipodystrophy. Its Canadian…Not currently marketed in Canada